EU regulator okays COVID-19 treatments from GSK-Vir and Sobi

Celltrion

16/12/2021 13:23

Dec 16 (Reuters) - The European Union's drug regulator on
Thursday approved a COVID-19 treatment from British-U.S. duo GSK
 GSK.L  and Vir Biotechnology  VIR.O  and another from Swedish
drugmaker Sobi  SOBIV.ST , as the bloc builds its defences
against Omicron.
    

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Omicron set to be Europe's dominant variant by early 2022 - ECDC
    urn:newsml:reuters.com:*:nL1N2T01DJ
COVID SCIENCE-Omicron thrives in airways, not lungs; new data on
asymptomatic cases     urn:newsml:reuters.com:*:nL1N2T02CQ
FACTBOX-Front runners in development of antibody drugs against
COVID-19     urn:newsml:reuters.com:*:nL8N2R81NW
FACTBOX-What COVID-19 vaccine and drug makers have to say about
Omicron     urn:newsml:reuters.com:*:nL4N2SN31Z
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (Reporting by Pushkala Aripaka and Amna Karimi in Bengaluru;
Editing by Edmund Blair)
 ((Amna.Karimi@thomsonreuters.com;))